Study of AlloGen® Liquid Intra-articular Injection for Knee Osteoarthritis

A Phase 1 Study Evaluating the Safety and Preliminary Efficacy of AlloGen® Liquid Intra-articular Injection for Knee Osteoarthritis

A randomized, double-blind, placebo-controlled trial comparing a single intra-articular injection of 2.0 mL AlloGen vs 2.0 mL sterile saline. Patients will be evaluated at baseline, 1 week, 6 weeks, 12 weeks, and 26 weeks.

Study Overview

• Status: Withdrawn
• Conditions: Osteoarthritis, Knee
• Intervention / Treatment: Drug: Placebo; Biological: AlloGen Liquid

Detailed Description

This is a Phase 1, randomized, double-blind, placebo-controlled trial comparing a single intra-articular 2.0 mL injection of either AlloGen or sterile saline. Patients will be evaluated at baseline, 1 week, 6 weeks, 12 weeks, and 26 weeks. The patient will remain blinded to his or her treatment throughout the study duration. The investigator/assessor will also remain blinded throughout the treatment period. Only the individual(s) preparing the injection will not be blinded. Black tape over the injection syringe will mask the study treatment.

Up to 30 adult patients with osteoarthritis of one knee that has failed to adequately respond to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen, will be enrolled at up to 5 sites in the US. The first 6 subjects will be staggered to evaluate any significant toxicity. Any adverse event data collected will be reviewed by the Data Safety Monitoring Board (DSMB) prior to treating the subsequent subject. Cumulative safety data from these 6 subjects will be reviewed by the DSMB.

• Study Type: Interventional
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject has both clinical and radiographic findings consistent with osteoarthritis of the knee:

  1. Subject has clinical findings including (but not limited to) tenderness to palpation, swelling/effusion, stiffness, chronic limited range of motion.
  2. Subject has a diagnosis of knee osteoarthritis (OA) defined as Grade 2 to 3 using the Kellgren-Lawrence grading scale.
• Failed conservative care over the past 3 months of at least 2 conservative treatments including oral pain medication [analgesics, steroids and/or non-steroidal anti-inflammatory drugs (NSAIDs)] and structured physical therapy or exercise program prescribed by physical therapist, chiropractor provider or physician specifically for the treatment of knee osteoarthritis.
• Subject has a BMI less than 40 kg/m2
• Subject is willing and able to provide informed consent and participate in all procedures and follow-up evaluations necessary to complete the study.
• Subject must have a VAS pain score of 4 or greater on a 100-mm scale.
• All subjects of reproductive age or capacity must use adequate contraception (abstinence, surgically sterilized, postmenopausal, or consistently use an effective contraception method) during the study.
• Subject agrees not to take additional knee symptom-modifying drugs (e.g., glucosamine, collagen, hyaluronic acid) during the study without reporting the use to the study team.

Exclusion Criteria:

• Subject has a diagnosis of knee osteoarthritis (OA) defined as Grade 4 on the Kellgren-Lawrence grading scale.
• Subject has active infection at the injection site.
• Subject has symptomatic OA of the contralateral knee or of either hip (VAS≥40) that is not responsive to acetaminophen (Tylenol®) and/or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs, e.g. Ibuprofen) and requires other therapy.
• Subject has rheumatoid arthritis, psoriatic arthritis, or has been diagnosed with any other disorders that is the primary source of their knee pain, including but not limited to:

osteonecrosis, radiculopathy, bursitis, tendinitis, tumor, cancer.

• Subject has documented history of gout or pseudo-gout.
• Subject has a known allergy to local anesthetics.
• Subject has autoimmune disease or a known history of having Acquired Immunodeficiency Syndromes (AIDS) or Human Immunodeficiency Virus (HIV).
• Subject has diagnosis of hematologic, renal, hepatic, or coagulation abnormalities based on medical history and laboratory results.

• Subject has received any of the following to the target knee:

  1. Intra-articular hyaluronic acid (HA) injection within 12 weeks prior to screening;
  2. Steroid or platelet rich plasma (PRP) injection within 12 weeks prior to screening;
  3. Has had or is planning to have major surgery in the target knee within 26 weeks of treatment; or
  4. History of unicondylar or total knee arthroplasty.
• Subject is currently participating in another clinical trial or has used an investigational drug, device or biologic within 12 weeks prior to treatment.
• Subject has a history of immunosuppressive use or chemotherapy in the last 12 months.
• Subject has had prior radiation to the index knee.
• Subject is currently taking anticoagulant therapy (excluding Plavix or Aspirin).
• Subject is breast feeding or pregnant or plans to become pregnant within 12 weeks of treatment.
• Subject has any significant medical condition that, in the opinion of the Investigator, would increase the chances of an adverse event and/or would interfere with protocol evaluation and participation.
• Subject is a worker's compensation patient.
• Subject has taken pain medication <48 hours prior to the injection or has received pain medicine other than acetaminophen and/or NSAIDs for conditions unrelated to OA of the index knee.
• Subject has a history of alcohol or substance abuse.

• Physical or IA injection exclusion criteria include:

  1. Frank mechanical symptoms such as locking, intermittent block to range of motion, or loose body sensations (meniscal displacement or IA loose body),
  2. Knee surgery on index knee within 12 months or on contralateral knee within 6 months, and/or
  3. Acute injury to the knee within 3 months.
• Subject has uncontrolled, unstable diabetes mellitus with HbA1C =/>8%.
• History within preceding 5 years of solid organ or hematologic transplantation or diagnosis of non-basal cell malignancy.
• History within the preceding 6 months of septic arthritis in the affected knee or sepsis/bacteremia.
• History within the preceding 3 months of infection requiring antibiotic treatment .

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: AlloGen Liquid; A single-dose, intra-articular (IA) injection of 2.0 mL of AlloGen Liquid administered to the affected knee.	Biological: AlloGen Liquid; Amniotic fluid
Placebo Comparator: Saline; A single-dose, intra-articular (IA) injection of 2.0 mL of saline administered to the affected knee.	Drug: Placebo; 0.9% normal saline

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the safety of intra-articular (IA) administration of AlloGen Liquid in the target knee	The incidence of related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events	Baseline to 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate preliminary efficacy of the injection by assessing pain subscale scores	Composite change from baseline in WOMAC-A (pain subscale) scores	Baseline, 6, 12 and 26 weeks
Evaluate preliminary efficacy of the injection by assessing function subscale scores	Composite change from baseline in WOMAC-C (function subscale) score	Baseline, 6, 12 and 26 weeks
Evaluate preliminary efficacy of the injection by assessing pain	Change from baseline in WOMAC-A scores	Baseline, 6, 12 and 26 weeks
Evaluate preliminary efficacy of the injection by assessing function	Change from baseline in WOMAC-C score	Baseline, 6, 12 and 26 weeks
Evaluate preliminary efficacy of the injection by Visual Analog Scale	Change from baseline in Visual Analog Scale (VAS)	Baseline, 6, 12 and 26 weeks
Evaluate preliminary efficacy of the injection by assessing total WOMAC	Change from baseline in total WOMAC score	Baseline, 6, 12 and 26 weeks
Evaluate the safety of intra-articular (IA) administration of AlloGen Liquid in the target knee	Incidence of related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events at 26 weeks	26 Weeks
Evaluate preliminary efficacy of the injection by assessing Patient-Reported Outcomes Measurement Information System (PROMIS)	Change from baseline in PROMIS pain interference and physical function scores	Baseline, 6, 12 and 26 weeks
Evaluate preliminary efficacy of the injection by assessing total SF-12 score	Change from baseline in total SF-12 score	Baseline, 6, 12 and 26 weeks
Evaluate preliminary efficacy of the injection by assessing total KOOS score	Change from baseline in total KOOS score	Baseline, 6, 12 and 26 weeks

Collaborators and Investigators

• Sponsor: VIVEX Biologics, Inc.
• Collaborators: MCRA
• Investigators: Principal Investigator: Brian Cole, MD, Brian Cole MD

Study record dates

Study Major Dates

• Study Start (Anticipated): June 1, 2021
• Primary Completion (Anticipated): March 1, 2022
• Study Completion (Anticipated): June 30, 2022

Study Registration Dates

• First Submitted: December 11, 2020
• First Submitted That Met QC Criteria: April 5, 2021
• First Posted (Actual): April 8, 2021

Study Record Updates

• Last Update Posted (Actual): July 8, 2021
• Last Update Submitted That Met QC Criteria: July 2, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Keywords: osteoarthritis; biologic
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee
• Other Study ID Numbers: AT-2021-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No